HEMOGLOBINOPATHY MARKET ANALYSIS

Hemoglobinopathy Market, by Test Type (Routine Red Blood Cell (RBC) count, Genetic Testing, Hemoglobin by high performance liquid chromatography, Hemoglobin isoelectric focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin solubility test), by Indication (Sickle Cell Disease, Beta Thalassemia, Alpha Thalassemia), by End User (Hospitals, Diagnostic Laboratories, Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023
Code : CMI2801
Pages :170
Formats :
Excel and PDF
Industry : Medical Devices

Market Challenges And Opportunities

Global Hemoglobinopathy Market: Restraint

Failing clinical trials for the treatment of sickle cell anemia

The global hemoglobinopathy market can be hindered by failing of clinical trials for the treatment of sickle cell anemia. For instance, in April 2022, Imara Inc., a clinical-stage biopharmaceutical company, announced that an Imara drug that hits a novel target to treat rare, inherited hemoglobin disorders has failed two mid-stage studies, one for sickle cell disease and the other for beta thalassemia.

Hemoglobinopathy Market Report Snapshots